ClinicalIntelPulse · Clinical Failure Analysis

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "failure_taxonomy": {
    "operational_failures": {
      "examples": [
        "COVID-19 disruption, enrollment failures in rare AD subpopulations"
      ],
      "pct": 4
    },
    "safety_termination": {
      "examples": [
        "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"
      ],
      "key_trials": [
        "Aducanumab Phase 3 dose arm"
      ],
      "pct": 8
    },
    "wrong_endpoint": {
      "examples": [
        "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"
      ],
      "key_trials": [
        "Multiple agents 2010-2020"
      ],
      "pct": 18
    },
    "wrong_patient_population": {
      "examples": [
        "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"
      ],
      "key_trials": [
        "Bapineuzumab (mild-moderate vs. early)"
      ],
      "pct": 28
    },
    "wrong_target_or_hypothesis": {
      "examples": [
        "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"
      ],
      "key_trials": [
        "Solanezumab",
        "Verubecestat",
        "Atabecestat"
      ],
      "pct": 42
    }
  },
  "historical_success_rates": {
    "overall_clinical_success_pct": 3.4,
    "phase2_to_phase3_pct": 31,
    "phase3_to_approval_pct": 11,
    "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)"
  },
  "lessons_learned": [
    "Early intervention is critical — treat pre-symptomatic or MCI only",
    "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)",
    "CDR-SB global score now accepted primary endpoint by FDA (post-2018)",
    "ARIA management protocols must be pre-specified — not post-hoc",
    "Combination approaches (amyloid + tau + neuroinflammation) likely needed"
  ],
  "query_summary": {
    "condition": "Alzheimer Disease",
    "trials_analyzed": 78
  },
  "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration.",
  "what_still_might_fail": [
    "Tau-targeting agents if amyloid clearance alone sufficient",
    "Agents tested in wrong disease stage despite lessons",
    "CNS inflammation approaches without biomarker stratification"
  ]
}